Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof

Abstract

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

What is claimed is: 
     
         1 . A composition of crystalline form CS1 of N-[(1,2-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-glycine, wherein the X-ray powder diffraction pattern of form CS1 shows characteristic peaks at 2theta values of 6.4° 00.2°, 7.5°±0.2°, and 7.9°±0.2° using CuKα radiation, and wherein the content of other crystalline forms is less than 10% (w/w). 
     
     
         2 . The composition according to  claim 1 , wherein the X-ray powder diffraction pattern of Form CS1 shows one or more characteristic peaks at 2theta values of 17.2°±0.2°, 21.0°±0.2°, 24.0°±0.2°, and 19.3°±0.2° using CuKα radiation. 
     
     
         3 . The composition according to  claim 1 , wherein the X-ray powder diffraction pattern of Form CS1 is substantially as depicted in  FIG.  1   . 
     
     
         4 . The composition according to  claim 1 , wherein the Form CS1 has an endothermic peak at around 242° C. as measured by differential scanning calorimetry using a heating rate of 10° C. min and a purge gas of nitrogen. 
     
     
         5 . The composition according to  claim 1 , wherein the chemical purity of Form CS1 is higher than 99%. 
     
     
         6 . The composition according to  claim 5 , wherein the chemical impurity remains substantially unchanged when the composition is stored under conditions of 60° C. 75% RH for 3 months. 
     
     
         7 . A composition of crystalline form CS9 of N-[(1,2-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-glycine, wherein the X-ray powder diffraction pattern of form CS9 shows characteristic peaks at 2theta values of 4.6°±0.2°, 6.6°±0.2°, and 21.1°±0.2° using CuKα radiation, and wherein the content of other crystalline forms is less than 10% (w/w). 
     
     
         8 . The composition according to  claim 7 , wherein the X-ray powder diffraction pattern shows one or more characteristic peaks at 2theta values of 9.4°±0.2°, 20.2°±0.2°, and 24.2°±0.2° using CuKα radiation. 
     
     
         9 . The composition according to  claim 7 , wherein the X-ray powder diffraction pattern of Form CS9 is substantially as depicted in  FIG.  6   . 
     
     
         10 . The composition according to  claim 7 , wherein the Form 9 has a first endothermic peak at around 145° C. and a second endothermic peak at around 237° C. as measured by differential scanning calorimetry using a heating rate of 10° C. min and a purge gas of nitrogen. 
     
     
         11 . The composition according to  claim 7 , wherein the chemical purity of Form CS9 is higher than 99%. 
     
     
         12 . The composition according to  claim 11 , wherein the chemical impurity remains substantially unchanged when the composition is stored under conditions of 60° C./5% RH for 1 month. 
     
     
         13 . A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of the composition of crystalline form CS1 according to  claim 1 , and pharmaceutically acceptable carriers, diluents or excipients. 
     
     
         14 . A pharmaceutical composition according to  claim 13 , wherein the crystalline form does not change following one-month storage at 40° C./5% RH. 
     
     
         15 . A method of treating anemia, comprising administering to a subject in need thereof a therapeutically effective amount of the composition of crystalline form CS1 according to  claim 1 . 
     
     
         16 . A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of the composition of crystalline form CS9 according to  claim 7 , and pharmaceutically acceptable carriers, diluents or excipients. 
     
     
         17 . A pharmaceutical composition according to  claim 16 , wherein the crystalline form does not change following one-month storage at 40° C./5% RH. 
     
     
         18 . A method of treating anemia, comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form CS9 according to  claim 7 .